NPCE250117P10000
- 0.00
- 0.000.00%
NeuroPace Newsroom
MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket
NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock?
Leerink Partners Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $18
Positive Outlook for NeuroPace: Anticipated Success of NAUTILUS Study and Strategic Market Advantage
NeuroPace, Inc. to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
NeuroPace Is Maintained at Overweight by JP Morgan
J.P. Morgan Maintains NeuroPace(NPCE.US) With Buy Rating, Raises Target Price to $14
NeuroPace: Undervalued Innovator in the Drug-Resistant Epilepsy Market With Promising Long-Term Growth
NeuroPace Price Target Raised to $14 From $9 at JPMorgan
Express News | Neuropace Inc : JP Morgan Raises Target Price to $14 From $9
NeuroPace to Host Investor Day on January 28th in New York City
Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting
NeuroPace Completes Enrollment In Feasibility Study Of RNS System For Lennox-Gastaut Syndrome; Received A $9.3M National Institutes Of Health Grant Through The Brain Research Through Advancing Innovative Neurotechnologies Initiative To Evaluate Its...
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome
Express News | Neuropace Completes Enrollment in Feasibility Study of Rns System for Lennox-Gastaut Syndrome
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $13
Strong Buy Recommendation for NeuroPace Amid Promising RNS System Results and Anticipated Market Advancements
What Makes NeuroPace (NPCE) a New Buy Stock